Our top pick for
Natera, Inc is a diagnostics & research business based in the US. Natera shares (NTRA) are listed on the NASDAQ and all prices are listed in US Dollars. Natera employs 1,039 staff and has a trailing 12-month revenue of around USD$361.9 million.
|52-week range||USD$16.87 - USD$127.19|
|50-day moving average||USD$114.0935|
|200-day moving average||USD$85.3392|
|Wall St. target price||USD$122.78|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||USD$-2.017|
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|Revenue TTM||USD$361.9 million|
|Gross profit TTM||USD$126.9 million|
|Return on assets TTM||-16.31%|
|Return on equity TTM||-60.74%|
|Market capitalisation||USD$9.5 billion|
TTM: trailing 12 months
There are currently 4.9 million Natera shares held short by investors – that's known as Natera's "short interest". This figure is 3.2% down from 5.0 million last month.
There are a few different ways that this level of interest in shorting Natera shares can be evaluated.
Natera's "short interest ratio" (SIR) is the quantity of Natera shares currently shorted divided by the average quantity of Natera shares traded daily (recently around 951865.88235294). Natera's SIR currently stands at 5.1. In other words for every 100,000 Natera shares traded daily on the market, roughly 5100 shares are currently held short.
However Natera's short interest can also be evaluated against the total number of Natera shares, or, against the total number of tradable Natera shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Natera's short interest could be expressed as 0.06% of the outstanding shares (for every 100,000 Natera shares in existence, roughly 60 shares are currently held short) or 0.0614% of the tradable shares (for every 100,000 tradable Natera shares, roughly 61 shares are currently held short).
A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the share price, with fewer people currently willing to bet against Natera.
Find out more about how you can short Natera stock.
We're not expecting Natera to pay a dividend over the next 12 months.
Over the last 12 months, Natera's shares have ranged in value from as little as $16.87 up to $127.19. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Natera's is 1.5107. This would suggest that Natera's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
Natera, Inc. provides preconception and prenatal genetic testing services. It offers Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus with a blood draw from the mother, as well as twin pregnancies for zygosity; Vistara, a single-gene mutations screening test to identify single-gene disorder; Horizon carrier screening to determine carrier status for various genetic diseases; and Spectrum to analyze chromosomal anomalies or inherited genetic conditions during an in vitro fertilization cycle. The company also provides Anora products of conception test to analyze fetal chromosomes to understand the cause of miscarriage; and non-invasive paternity testing products to determine paternity by analyzing the fragments of fetal deoxyribonucleic acid in a pregnant mother's blood and a blood sample from the alleged father. In addition, it offers Constellation, a cloud-based software product that allows laboratory customers to gain access through the cloud to the company's algorithms and bioinformatics in order to validate and launch tests; and Signatera, a circulating tumor DNA technology that analyzes and tracks mutations to an individual's tumor. The company offers products through its direct sales force, as well as through a network of approximately 100 laboratory and distribution partners in the United States and internationally. It has a partnership agreement with BGI Genomics Co., Ltd. to develop, manufacture, and commercialize NGS-based genetic testing assays; and Foundation Medicine, Inc. to develop and commercialize personalized circulating tumor DNA monitoring assays. The company was formerly known as Gene Security Network, Inc. and changed its name to Natera, Inc. in 2012. Natera, Inc. was founded in 2003 and is headquartered in San Carlos, California.
Everything we know about the Toast Inc IPO, plus information on how to buy in.
Everything we know about the Cyxtera IPO, plus information on how to buy in.
Everything we know about the ATI Physical Therapy IPO, plus information on how to buy in.
Everything we know about the Sportradar IPO, plus information on how to buy in.
Everything we know about the Longboard Pharmaceuticals Inc IPO, plus information on how to buy in.
Everything we know about the Prometheus Biosciences Inc IPO, plus information on how to buy in.
Everything we know about the Olo Inc IPO, plus information on how to buy in.
Everything we know about the China Eco-Materials Group Co Limited IPO, plus information on how to buy in.
Everything we know about the Gain Therapeutics Inc IPO, plus information on how to buy in.
Everything we know about the Karat Packaging Inc IPO, plus information on how to buy in.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.